Advanced Mammography Systems will enjoy its first RSNA meetingwith 510(k) clearance for its Aurora 0.5-tesla dedicated MR mammographyscanner, which it is marketing at a list price of about $500,000.AMS, of Wilmington, MA, received the Food and Drug
Advanced Mammography Systems will enjoy its first RSNA meetingwith 510(k) clearance for its Aurora 0.5-tesla dedicated MR mammographyscanner, which it is marketing at a list price of about $500,000.AMS, of Wilmington, MA, received the Food and Drug Administration'simprimatur in February, and the first beta unit was installedat the Breast Imaging Center at the University of Texas MedicalBranch in Galveston. That center has examined over 200 women withthe system, AMS reported last month.
Aurora is an important part of a new corporate strategy adoptedearlier this year by AMS parent Advanced NMR Systems, which wasforced to shut down its InstaScan echo-planar imaging effort dueto slow sales (SCAN 6/19/96). Advanced NMR intends to open a networkof Aurora Breast Imaging centers to offer MR mammography services.The first such center will be installed in early 1997 at the Faulkner-SagoffCentre for Breast Health Care at Faulkner Hospital in Boston.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.